Chimeric Therapeutics Limited (ASX: CHM)
Health Care · Biotechnology · AU
AU$—
— today · — 1Y
Chimeric Therapeutics Limited (ASX: CHM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $246.44K and employs 3 people.
trading between 0.00 and 0.40.
Tweenvest scores Chimeric Therapeutics Limited across four factors: quality 21/100, value 18/100. Its strongest factor is quality.
CHM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $246.44K
- Revenue (TTM)
- $-131.34K
- P/E
- —
- EPS
- -0.61
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- AU$0.40
- 52-week low
- AU$0.00
- Avg volume (3M)
- —
- Shares outstanding
- 118.13M
- Employees
- 3
- Next earnings
- —
About Chimeric Therapeutics Limited
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
- ISIN
- AU0000121576
- Founded
- 2020
- Listed since
- Jan 17, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Longevity Health Holdings, Inc.OTCPK: XAGE | $277.24K | $0.11 | +0.90% |
| Sorrento Therapeutics, Inc.OTCPK: SRNE | $271.86K | $0.00 | -37.50% |
| Albert Labs International Corp.CNSX: ABRT | $271.79K | CA$— | — |
| Zenith Capital Corp.OTCPK: ZHCL.F | $257.79K | $0.00 | +300.00% |
| Nextel Medical Corp.OTCPK: MAJI | $239.24K | $0.00 | -2.93% |
| WPD Pharmaceuticals Inc.CNSX: WBIO | $233.63K | CA$— | — |
| Beroni Group LimitedOTCPK: BNIG.F | $216.88K | $— | — |
| NAVCO Pharmaceuticals Inc.TSXV: NAV | $200.86K | CA$0.01 | — |
Figures last refreshed Oct 18, 2026.